(VRDN) Viridian Therapeutics - Ratings and Ratios

Viridian Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for rare and serious diseases. Its pipeline includes veligotug, a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), currently in Phase 3 clinical trials for thyroid eye disease (TED). Additionally, VRDN-003, a next-generation IGF-1R monoclonal antibody with half-life extension technology, is also in Phase 3 trials for TED. The company is further expanding its portfolio with engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008, for autoimmune diseases. Formerly known as Miragen Therapeutics, Inc., the company rebranded as Viridian Therapeutics in January 2021 and is headquartered in Waltham, Massachusetts.

From a technical standpoint, VRDN stock is trading below its 20-day SMA of 12.85 and 50-day SMA of 14.21, but above its 200-day SMA of 18.05, indicating mixed near-term momentum. The average trading volume over 20 days is 1,035,120 shares, with a last price of 13.62 and an ATR of 0.94, suggesting moderate volatility. Fundamentally, the company has a market cap of $1.07 billion, a price-to-book ratio of 2.22, and a price-to-sales ratio of 3,542.71, reflecting its high valuation relative to sales. The return on equity is -40.19%, highlighting ongoing losses. Based on these metrics, the stock may face near-term pressure due to its high P/S ratio and negative profitability, but its pipeline progress could offset these challenges in the longer term.